Session Information
Date: Monday, September 23, 2019
Session Title: Genetics
Session Time: 1:45pm-3:15pm
Location: Les Muses Terrace, Level 3
Objective: The aim of our study was to to determine if serum mir-96-5p and mir-339-5p can be used as biomarkers for early diagnosis of Parkinson’s disease(PD) and/or Multiple System Atrophy (MSA). Moreover, we assessed relationships between miR-96-5p and miR-339-5p dysregulation and clinical features in both diseases.
Background: Despite growing research efforts, no reliable biomarker currently exists for the early diagnosis and prognosis of PD and MSA. MicroRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression inducing translational repression or mRNA degradation of specific gene target. They can also be released from the cells and enter into circulatory biofluids such as blood, serum, plasma, saliva, and urine.Several studies have identified many miRNAs specifically deregulated in PD and MSA patients. Moreover, different groups, including ours, have found that several circulating miRNAs are differently expressed in the serum samples of MSA subjects compared to PD patients and healthy controls (HC).
Method: In our study, we enrolled 65 patients affected by PD, 70 patients with MSA (65±7 years) and 60 healthy controls (HC) (64,66±12 years). Using miRcury LNA assay, we analyzed serum mir-96-5p and miR-339-5p in MSA and PD samples compared with HC.
Results: We observed that miR-96-5p-5p was significantly up-regulated in MSA and PD as compared with HC. MiR-339-5p was was significantly up-regulated in MSA compared with HC and also downregulated in PD compared with PD. Our results suggest that serum mir-339-5p can discriminate PD from MSA patients from HC and deserves to be further assessed as a specific, non-invasive biomarker for differential diagnosis of parkinsonisms.
Conclusion: Prospective studies on larger cohorts are warranted to confirm whether miR96-5p and miR-339-5p can be useful for the early diagnosis of parkinsonisms.
To cite this abstract in AMA style:
A. Vallelunga, T. Iannitti, S. Capece, G. Somma, G. Dati, P. Barone, W. Meissner, M. Pellecchia. Serum MIR-96-5P and MIR-339-5P as a Potential Biomarker for Multiple System Atrophy and Parkinson’s Disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/serum-mir-96-5p-and-mir-339-5p-as-a-potential-biomarker-for-multiple-system-atrophy-and-parkinsons-disease/. Accessed June 14, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/serum-mir-96-5p-and-mir-339-5p-as-a-potential-biomarker-for-multiple-system-atrophy-and-parkinsons-disease/